Sentinel Lymph Node Biopsy Positivity in Patients With Acral Lentiginous and Other Subtypes of Cutaneous Melanoma
- PMID: 34878492
- PMCID: PMC8655663
- DOI: 10.1001/jamadermatol.2021.4812
Sentinel Lymph Node Biopsy Positivity in Patients With Acral Lentiginous and Other Subtypes of Cutaneous Melanoma
Abstract
Importance: Acral lentiginous melanoma (ALM) is a rare subtype of malignant melanoma typically occurring on the palmar and plantar surfaces. Although it has distinctive genetic, prognostic, and behavioral characteristics relative to cutaneous melanomas overall, owing to its rarity, treatment is largely guided by data extrapolated from more common subtypes. Although sentinel lymph node (SLN) status has been shown to be a significant prognostic factor for ALM, the independent effect of ALM-subtype disease on the likelihood of SLN positivity and the stage-specific positivity rates for ALM are not well characterized.
Objective: To evaluate the association of ALM with SLN status as well as to characterize the clinical stage-specific rates of SLN positivity for ALM based on the AJCC Cancer Staging Manual, 8th edition (AJCC-8).
Design, setting, and participants: The National Cancer Database (NCDB) includes all reportable cases from Commission on Cancer accredited facilities and represents approximately 50% of all newly diagnosed melanoma cases in the US. This retrospective cohort study included cases of AJCC-8 clinical stage I to II melanomas from the NCDB diagnosed from 2012 to 2015. The analysis took place between April 2021 and September 2021.
Exposures: Melanoma histopathologic subtype.
Main outcomes and measures: Sentinel lymph node status.
Results: We identified 60 148 patients with malignant melanomas, 959 of whom had ALM-subtype disease. Among patients in the cohort, 25 550 (42.5%) were women and the mean (SD) age was 64 (16) years. Multivariable logistic regression controlling for demographic and histopathologic characteristics revealed that ALM was independently associated with the highest risk for SLN positivity among included subtypes (vs superficial spreading melanoma: odds ratio, 1.91; 95% CI, 1.59-2.28). Subgroup analysis by AJCC clinical stage demonstrated that ALM was independently associated with the highest risk for SLN positivity for both stage IB and II disease. The rate of SLN positivity for patients with stage IB and II ALM was 18.39% (95% CI, 13.82%-24.03%) and 39.53% (34.98%-44.26%), respectively.
Conclusions and relevance: In this cohort study ALM was independently associated with SLN positivity and had relatively high positivity rates at clinical stage IB and II. This suggests that SLNB should be encouraged for all patients with clinical stage IB and II ALM, and such patients should receive appropriate counseling about the higher regional metastatic risk of their cancers. Future work with a larger cohort is required to elucidate the risk of SLN positivity for stage IA ALM.
Conflict of interest statement
Figures
Comment in
-
Relationships between tumor thickness and the risk of sentinel node metastasis in acral and non-acral melanoma.Int J Dermatol. 2023 Nov;62(11):e573-e575. doi: 10.1111/ijd.16771. Epub 2023 Jun 30. Int J Dermatol. 2023. PMID: 37387547 No abstract available.
Similar articles
-
American Joint Committee on Cancer clinical stage as a selection criterion for sentinel lymph node biopsy in thin melanoma.Ann Surg Oncol. 2006 Feb;13(2):198-204. doi: 10.1245/ASO.2006.03.092. Epub 2006 Jan 19. Ann Surg Oncol. 2006. PMID: 16418885
-
Does sentinel lymph node status have prognostic significance in patients with acral lentiginous melanoma?J Surg Oncol. 2019 Jun;119(8):1060-1069. doi: 10.1002/jso.25445. Epub 2019 Mar 18. J Surg Oncol. 2019. PMID: 30883783
-
Prognostic significance of acral lentiginous histologic type in T1 melanoma.Mod Pathol. 2021 Mar;34(3):572-583. doi: 10.1038/s41379-020-0641-x. Epub 2020 Aug 5. Mod Pathol. 2021. PMID: 32759976
-
Sentinel lymph node biopsy in patients with primary cutaneous melanoma: study of 455 cases.J Eur Acad Dermatol Venereol. 2000 Jan;14(1):35-45. doi: 10.1046/j.1468-3083.2000.00005.x. J Eur Acad Dermatol Venereol. 2000. PMID: 10877250 Review.
-
Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.Recent Results Cancer Res. 2000;157:178-89. doi: 10.1007/978-3-642-57151-0_15. Recent Results Cancer Res. 2000. PMID: 10857171 Review.
Cited by
-
Prognostic and Predictive Significance of Ki67 in Primary Non-metastatic or Recurrent Acral Melanoma: Evidence from a Multicenter Retrospective Study.Ann Surg Oncol. 2024 Jul;31(7):4594-4604. doi: 10.1245/s10434-024-15327-4. Epub 2024 Apr 30. Ann Surg Oncol. 2024. PMID: 38689172
-
Sentinel lymph node biopsy versus observation in high risk cutaneous squamous cell carcinoma of head and neck: a propensity score matching analysis.Arch Dermatol Res. 2024 Apr 16;316(5):120. doi: 10.1007/s00403-024-02870-z. Arch Dermatol Res. 2024. PMID: 38625390
-
Primary Melanoma Histopathologic Predictors of Sentinel Lymph Node Positivity: A Proposed Scoring System for Risk Assessment and Patient Selection in a Clinical Setting.Medicina (Kaunas). 2023 Oct 30;59(11):1921. doi: 10.3390/medicina59111921. Medicina (Kaunas). 2023. PMID: 38003969 Free PMC article.
-
Role of Sentinel Lymph Node Biopsy for Skin Cancer Based on Clinical Studies.Cancers (Basel). 2023 Jun 22;15(13):3291. doi: 10.3390/cancers15133291. Cancers (Basel). 2023. PMID: 37444401 Free PMC article. Review.
-
Redesigning Sentinel Lymph Node Biopsy Guidelines in Melanoma Cases.Eplasty. 2023 Feb 3;23:e8. eCollection 2023. Eplasty. 2023. PMID: 36817365 Free PMC article. Review.
References
-
- National Comprehensive Cancer Network . NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Melanoma (Version 2.2021). Accessed July 7, 2021. https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf
-
- Weber J, Del Vecchio M, Mandala M, et al. . Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial. Ann Oncol. 2019;30:v533-v534. doi:10.1093/annonc/mdz255 - DOI
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous